PTC Therapeutics, Inc. filed a current report on November 3, 2026, disclosing that its Board of Directors authorized a share repurchase program of up to $500.0 million of the company's common stock.

Key Highlights

  • Repurchase authorization: PTC Therapeutics' Board authorized repurchases of up to $500.0 million of the company's common stock, par value $0.001 per share.
  • Repurchase methods: Permitted methods include open-market transactions, pre-set trading plans, privately negotiated transactions, and accelerated share repurchases, among others.
  • Management discretion: Share repurchases may be made from time to time at management's discretion in accordance with applicable securities laws.
  • Reporting commitment: Information regarding any share repurchases will be disclosed in the company's periodic reports filed with the SEC as required by applicable Exchange Act rules.
  • Exchange listing: The company's common stock trades on NASDAQ:PTCT on the Nasdaq Global Select Market.

PTC Therapeutics Announces $500 Million Common Stock Repurchase Authorization

According to the filing, PTC Therapeutics, Inc., a Delaware-incorporated biopharmaceutical company headquartered at 500 Warren Corporate Center Drive, Warren, NJ, disclosed on November 3, 2026 that its Board of Directors authorized a new share repurchase program. Under the program, the company may repurchase up to $500.0 million of its common stock, which carries a par value of $0.001 per share. The disclosure was made under both Item 7.01 (Regulation FD) and Item 8.01 (Other Information) of the current report.

The filing states that repurchases may be executed through a variety of methods, including open-market transactions with pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions conducted in accordance with applicable securities laws. The filing further notes that the timing and execution of any repurchases will be at management's discretion. The company indicated that updates on repurchase activity will appear in future quarterly and annual reports filed with the SEC. The filing was signed by Pierre Gravier, Chief Financial Officer of PTC Therapeutics, Inc.

The filing specifies that the information furnished under Item 7.01, including the attached press release as Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." This distinction, stated in the filing's own language, relates to the liability provisions of that section and to incorporation by reference in other filings under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

What Was Disclosed

PTC Therapeutics reported that its Board of Directors authorized a share repurchase program of up to $500.0 million of common stock on November 3, 2026, with repurchases to occur at management's discretion through multiple permitted transaction types.